OptimiTM-03.jpg
Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
May 17, 2023 08:15 ET | Optimi Health Corp.
VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
OptimiTM-03.jpg
Optimi Health Granted Natural Health Product Site Licence By Health Canada
May 10, 2023 08:45 ET | Optimi Health Corp.
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
OptimiTM-03.jpg
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
May 04, 2023 09:00 ET | Optimi Health Corp.
VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a...
OptimiTM-03.jpg
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
March 01, 2023 07:30 ET | Optimi Health Corp.
Highlights:  Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
OptimiTM-03.jpg
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
February 07, 2023 10:31 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...
OptimiTM-03.jpg
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
February 06, 2023 08:30 ET | Optimi Health Corp.
The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under...
Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements
January 17, 2023 09:00 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...
OptimiTM-03.jpg
Optimi Health Announces Re-Appointments to Board of Directors
January 10, 2023 16:15 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik,...
OptimiTM-03.jpg
Optimi Health Announces Closing of Strategic Non-Brokered Private Placement
October 11, 2022 09:00 ET | Optimi Health Corp.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. Highlights: ...
OptimiTM-03.jpg
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
October 06, 2022 12:51 ET | Optimi Health Corp.
Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable...